COMBINED THERAPY FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS USING ATORVASTATIN AND FENOFIBRATE: EFFICACY AND SAFETY EVALUATION

Statins are the agents of choice of the lipid - lowering therapy at type 2 diabetes mellitus [1, 3]. Fibrates are usually used at hypertriglyceridemia and the low concentratio n of high - density lipoprotein cholesterol [4, 6]. The experience of using the combination of anticholesterol drugs at type 2 diabetes mellitus is limited in Russia. During 1 year 30 patients with type 2 diabetes mellitus have been receiving the combined li pid - lowering therapy with 20 mg of atorvastatin a day and 145 mg of micronized fenofibrate a day. 44 patients with type 2 diabetes mellitus did not take anticholesterol drugs as they refused from the conducted therapy. The efficiency, acceptability and saf ety of this therapy at type 2 diabetes mellitus were evaluated. The combined therapy with atorvastatin and micronized fenofibrate during one year has significant lipid - lowering effect. This combination of drugs has no negative effect on carbohydrate metabo- lism, on course of diabetic microangiopathy and is safe for patients with type 2 diabetes mellitus during 1 year.